Cassava Sciences reported $114.82M in Current Assets for its fiscal quarter ending in June of 2025.




Current Assets Change Date
Abbott USD 24.47B 1.32B Jun/2025
Amgen USD 26.73B 195M Jun/2025
Biogen USD 7.97B 341.7M Jun/2025
Cassava Sciences USD 114.82M 21.71M Jun/2025
Eisai JPY 763.15B 35.49B Jun/2025
Eli Lilly USD 49.85B 8.59B Jun/2025
Geron USD 505.6M 9.83M Jun/2025
J&J USD 71.55B 15.66B Mar/2025
Merck USD 37.07B 1.56B Jun/2025
Novartis USD 25.94B 831M Jun/2025
Pfizer USD 43.7B 2.16B Jun/2025
Roche Holding CHF 40.04B 6.41B Dec/2024